CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

POSITIVE PROFIT ALERT

This announcement is made by CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the voluntary announcements of the Company dated 30 January 2026 and 29 May 2026, respectively, in relation to a) the strategic collaboration and license agreement entered into between the Group and AstraZeneca to develop innovative long-acting peptide medicines (the "**Agreement**"); and b) the receipt of the upfront payment of US$1,200 million (the "**Upfront Payment**") by the Group in May 2026 pursuant to the terms of the Agreement.

The Board of Directors of the Company (the "**Board**") wishes to inform the shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Reporting Period**") and the information currently available to the Board, the Group is expected to record a consolidated profit attributable to owners of the Company for the Reporting Period within the range of RMB5,900 million to RMB6,200 million, representing a significant increase as compared to the consolidated profit attributable to owners of the Company of approximately RMB2,550 million for the six months ended 30 June 2025. The primary reason for such increase is mainly attributable to the combined effect of the following factors:

1. Significant increase in licence fee income compared with the same period last year

US$840 million (equivalent to approximately RMB5,740 million) of the Upfront Payment is expected to be recognised as licence fee income for the second quarter of 2026, making a significant revenue contribution to the Group during the Reporting Period.

2. **Stable growth in sales revenue from finished drugs business, excluding the impact of licence fee income**

   Excluding the impact of the aforesaid licence fee income for the first half of 2026, the sales revenue of the finished drugs business during the Reporting Period increased by approximately 10% compared with the same period last year, continuing to provide solid support for the overall profit of the Group.

As at the date of this announcement, the Company is still in the process of finalising the interim results of the Group for the Reporting Period. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group currently available and other information, which have not been reviewed or audited by the Company's independent auditor, nor reviewed by the audit committee of the Company. As the interim results have not yet been finalised as at the date of this announcement, the actual financial results of the Group for the Reporting Period may differ from what is disclosed in this announcement. The Company expects to publish the interim results announcement of the Group for the six months ended 30 June 2026 on 20 August 2026.

Shareholders and potential investors of the Company are advised to exercise caution and not to place undue reliance on the information disclosed in this announcement when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.